Home > Publications > Medical Specialty > Neurology > Neurology > ECTRIMS 2024 Conference Review
ECTRIMS 2024 Conference Review

ECTRIMS 2024 Conference Review

In this review:
–  Revised McDonald criteria 2023
–  Does high-dose simvastatin slow progression of disability in SPMS?
–  Efficacy of tolebrutinib in non-relapsing SPMS: the HERCULES trial
–  New clinical subtypes of MS identified
–  Unveiling specialists’ views on MS prognostication
–  Misdiagnosis of MS in an adult neurogenetics clinic
–  Safety and efficacy of frexalimab in RMS
–  Short-term B cell depletion results in long-term freedom from disease activity in some RMS patients
–  Impact of alternate-day fingolimod tapering on rebound disease activity in MS
–  B cell tailored dosing vs standard interval dosing of ocrelizumab
–  High efficacy treatment discontinuation vs continuation in patients older than 50 with stable MS

You need to be logged in to access this content.

John-Mottershead

Expert contributor

Dr John Mottershead

Dr John Mottershead is a Neurologist at Te Whatu Ora–Southern. He trained at Oxford University as a medical student and after qualification and junior doctor jobs was involved in research into uses of MRI in MS under the supervision of Professor Ian McDonald at Queen Square, London, before completing his neurology training in the South […]

Latest Publications and Videos

Stay up to date with our latest clinical information.

Explore Research Review Publications and Videos

Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry. 

Find Reviews in Your Clinical Area
Please select your country of practice.
Terms and Conditions

Website terms of use 

By using our website, you agree to follow these terms and conditions. 

 

Privacy policy 

We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms. 

 

Copyright and use of website content 

The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use. 

You cannot:  copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission. 

 

Links to third-party websites 

The Research Review website may link to third-party websites for your convenience. However: 

We do not endorse or approve their products, services, or actions. 

We are not responsible for their content or how they operate. 

There is no formal partnership between us and third parties unless we clearly state otherwise. 

 

Disclaimer and limitation of liability 

We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date. 

To the fullest extent allowed by law, we are not responsible for: 

Any loss, damage, or costs you may suffer from using (or being unable to use) our website. 

Any decisions you make based on the information provided. 

Any business losses, such as lost profits, lost data, or business interruptions. 

 

Governing law 

These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court. 

It looks like you are closest to our Australia site.